Shelby Livingston

Chatted with GoodRx's new CEO Wendy Barnes. She's focused on speeding up its current growth plans, like leaning into brand name drugs. “The rails exist, but we’ve just got to throw more trains on it. We’ve got to really expand the same strategy.” https://t.co/lXISY4nW4F

RT @ArmstrongDrew: The @endpts Health Tech newsletter is a @SABEW winner! Congrats to @lydiapflanzer, @ShelbyJLiv + @nyeungs for building a…

Seeing a ton of reports saying Hims will stop compounding semaglutide (Ozempic/Wegovy). That's incorrect. Hims will no longer offer exact copies, but they will offer semaglutide in dosages that aren't commercially available. Already, that's mostly what they do for GLP-1 users.

No semaglutide shortage, no problem. Hims said Monday that its weight loss biz is projected to drive at least $725 million in revenue this year — almost a third of the revenue Hims expects to pull in across the entire company. https://t.co/fwOWFyOUZZ

Since the murder of UnitedHealth's top insurance exec and outpouring of public frustration with delayed and denied care, a major question has circled the giant: Will it change how it does business? So far there’s little sign big reforms are in the works. https://t.co/2ZX1AFJrfc

RT @endpts: We've noticed a huge number of people in the science and medical community joining @bluesky . Endpoints and many of our journal…

When you keep your enemies close... Eli Lilly and Ro have formed an unlikely partnership, with Ro now offering cash-pay Zebpound vials through its app. Recall that Ro has offered compounded GLP-1 drugs, which Lilly and Novo have railed against. https://t.co/AY7mFZyUPD

The cold-blooded shooting of UnitedHealthcare CEO Brian Thompson sent shockwaves through corporate America, highlighting the threats increasingly faced by healthcare execs and workers and prompting companies to rethink how they keep their top brass safe. https://t.co/XToOS7vErz

NEW this morning: With direct-to-patient services for obesity drugs facing scrutiny, the telehealth startup Ro is trying to prove that its online weight loss program is up to snuff. https://t.co/LuzODDajTP

23andMe is getting out of drug development https://t.co/1gofMlElBZ

RT @MaxGelman: Biotech industry worries over potential for RFK Jr. ally as FDA pick https://t.co/H6iXZYc9iJ

RT @lydiapflanzer: It's going to be hard to put the compounding pharmacy genie back in the bottle, @ShelbyJLiv writes in today's edition o…

Lilly CEO Dave Ricks brushed off concerns that compounding pharmacies pose a threat to Zepbound sales, claiming compounding "certainly isn't" a "crisis" for the company. https://t.co/67gvAzsXe2

The hottest companies at this year’s HLTH weren’t buzzy startups with billions in backing for a new approach to disrupt the healthcare industry. They were compounding pharmacies: the companies responsible for creating cheap imitations of branded drugs. https://t.co/gT9uY7TFCz https://t.co/XvL5zdy5Jy

MGM Resorts plans to stop covering GLP-1 weight loss shots for its employees next year, after it faced constraints in what it could do to manage soaring costs without losing crucial drug discounts, a top benefits director said. https://t.co/JpHfOEyjb0

Had a blast talking GLP-1 coverage, PBM rebates, and compounding with execs from @MGMResortsIntl, @ww_us, @Accolade and @larkhealth at #HLTH2024. See ya, Vegas! https://t.co/a3ySmNp1uj

RT @ZacharyBrennan: #HLTH24: 'It’s not right.' Califf slams pharma over weight loss drug prices - https://t.co/UfE9QlMAhW